The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
EFNS guidelines on management of narcolepsy
Open accessAbstract
Management of narcolepsy with or without cataplexy relies on several classes of drugs, namely stimulants for excessive daytime sleepiness and irresistible episodes of sleep, antidepressants for cataplexy and hypnosedative drugs for disturbed nocturnal sleep. In addition, behavioral measures can be of notable value. Guidelines on the management of narcolepsy have already been published. However contemporary guidelines are necessary given the growing use of modafinil to treat excessive daytime sleepiness in Europe within the last 5–10 years, and the decreasing need for amphetamines and amphetamine‐like stimulants; the extensive use of new antidepressants in the treatment of cataplexy, apart from consistent randomized placebo‐controlled clinical trials; and the present re‐emergence of gamma‐hydroxybutyrate under the name sodium oxybate, as a treatment of all major symptoms of narcolepsy. A task force composed of the leading specialists of narcolepsy in Europe has been appointed. This task force conducted an extensive review of pharmacological and behavioral trials available in the literature. All trials were analyzed according to their class evidence. Recommendations concerning the treatment of each single symptom of narcolepsy as well as general recommendations were made. Modafinil is the first‐line pharmacological treatment of excessive daytime sleepiness and irresistible episodes of sleep in association with behavioral measures. However, based on several large randomized controlled trials showing the activity of sodium oxybate, not only on cataplexy but also on excessive daytime sleepiness and irresistible episodes of sleep, there is a growing practice in the USA to use it for the later indications. Given the availability of modafinil and methylphenidate, and the forseen registration of sodium oxybate for narcolepsy (including excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep) in Europe, the place of other compounds will become fairly limited. Since its recent registration cataplexy sodium oxybate has now become the first‐line treatment of cataplexy. Second‐line treatments are antidepressants, either tricyclics or newer antidepressants, the later being increasingly used these past years despite few or no randomized placebo‐controlled clinical trials. As for disturbed nocturnal sleep the best option is still hypnotics until sodium oxybate is registered for narcolepsy. The treatments used for narcolepsy, either pharmacological or behavioral, are diverse. However the quality of the published clinical evidences supporting them varies widely and studies comparing the efficacy of different substances are lacking. Several treatments are used on an empirical basis, specially antidepressants for cataplexy, due to the fact that these medications are already used widely in depressed patients, leaving little motivation from the manufacturers to investigate efficacy in relatively rare indications. Others, in particular the more recently developed substances, such as modafinil or sodium oxybate, are evaluated in large randomized placebo‐controlled trials. Our objective was to reinforce the use of those drugs evaluated in randomized placebo‐controlled trials and to reach a consensus, as much as possible, on the use of other available medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769
PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY
NISHINO, S., & MIGNOT, E. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00070-6 · Cited by 449
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
Fry, & US Modafinil in Narcolepsy Multicenter Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410430115 · Cited by 396
Brainin, M., Barnes, M., Baron, J. ‐., Gilhus, N. E., Hughes, R., Selmaj, K., & Waldemar, G. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00867.x · Cited by 375
Boeve, B. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00072-8 · Cited by 366
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
US Modafinil in Narcolepsy Multicenter Study Group (2000) · Neurology · doi:10.1212/wnl.54.5.1166 · Cited by 362
Modafinil Binds to the Dopamine Uptake Carrier Site with Low Affinity
Mignot, E., Nishino, S., Guilleminault, C., & Dement, W. C. (1994) · Sleep · doi:10.1093/sleep/17.5.436 · Cited by 318
Broughton, R. J., Fleming, J. A. E., George, C. F. P., Hill, J. D., Kryger, M. H., Moldofsky, H., Montplaisir, J. Y., Morehouse, R. L., Moscovitch, A., & Murphy, W. F. (1997) · Neurology · doi:10.1212/wnl.49.2.444 · Cited by 288
Leone, M. A., Brainin, M., Boon, P., Pugliatti, M., Keindl, M., & Bassetti, C. L. (2013) · European Journal of Neurology · doi:10.1111/ene.12043 · Cited by 280
Self-citationSodium Oxybate Improves Excessive Daytime Sleepiness in Narcolepsy
Black, J., & Houghton, W. C. (2006) · Sleep · doi:10.1093/sleep/29.7.939 · Cited by 234
Treatment of Narcolepsy with γ-Hydroxybutyrate. A Review of Clinical and Sleep Laboratory Findings
Mamelak, M., Scharf, M. B., & Woods, M. (1986) · Sleep · doi:10.1093/sleep/9.1.285 · Cited by 231
Gelineau, J. (1880) · Medical Entomology and Zoology · Cited by 205
Lin, J. S., Roussel, B., Akaoka, H., Fort, P., Debilly, G., & Jouvet, M. (1992) · Brain Research · doi:10.1016/0006-8993(92)91713-o · Cited by 203
Health-Related Quality of Life Effects of Modafinil for Treatment of Narcolepsy
Beusterien, K. M., Rogers, A. E., Walsleben, J. A., Emsellem, H. A., Reblando, J. A., Wang, L., Goswami, M., & Steinwald, B. (1999) · Sleep · doi:10.1093/sleep/22.6.757 · Cited by 183
Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., & Nishino, S. (2003) · Sleep · doi:10.1093/sleep/26.8.953 · Cited by 179
Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study
Lammers, G. J., Arends, J., Declerck, A. C., Ferrari, M. D., Schouwink, G., & Troost, J. (1993) · Sleep · doi:10.1093/sleep/16.3.216 · Cited by 179
Self-citationU.S. Xyrem® Multicenter Study Group (2003) · SLEEP · doi:10.1093/sleep/26.1.31 · Cited by 175
Study Group, U. S. X. M. (2004) · Sleep Medicine · doi:10.1016/j.sleep.2003.11.002 · Cited by 173
Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset
Dauvilliers, Y., Carlander, B., François, Touchon, J., & Tafti, M. (2004) · Annals of Neurology · doi:10.1002/ana.20339 · Cited by 167
Self-citationMamelak, M., Black, J., Montplaisir, J., & Ristanovic, R. (2004) · Sleep · doi:10.1093/sleep/27.7.1327 · Cited by 165
The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate
Broughton, R., & Mamelak, M. (1979) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100119304 · Cited by 163
Modafinil: A Double-Blind Multicentric Study
Billiard, M., Besset, A., Montplaisir, J., Laffont, F., Goldenberg, F., Weill, J. S., & Lubin, S. (1994) · Sleep · doi:10.1093/sleep/17.suppl_8.s107 · Cited by 162
Self-citationreg, T. X., & International Study Group (2005) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26368 · Cited by 158
Mitler, M. M., Harsh, J., Hirshkowitz, M., & Guilleminault, C. (2000) · Sleep Medicine · doi:10.1016/s1389-9457(00)00031-9 · Cited by 147
Guilleminault, C., Raynal, D., Takahashi, S., Carskadon, M. A., & Dement, W. C. (1976) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1976.tb07621.x · Cited by 145
Increased Production of Evoked and Spontaneous K-complexes Following a Night of Fragmented Sleep
Nicholas, C. L., Trinder, J. C., & Colrain, I. M. (2002) · SLEEP · doi:10.1093/sleep/25.8.42 · Cited by 144
Narcolepsy and its treatment with stimulants. ASDA standards of practice.
Mitler, M. M., Aldrich, M. S., Koob, G. F., & Zarcone, V. P. (1994) · PubMed · Cited by 141
Evaluation of Treatment With Stimulants in Narcolepsy
Mitler, M. M. (1994) · SLEEP · doi:10.1093/sleep/17.suppl_8.s103 · Cited by 141
Lecendreux, M., Maret, S., Bassetti, C. L., Mouren, M., & Tafti, M. (2003) · Journal of Sleep Research · doi:10.1046/j.1365-2869.2003.00380.x · Cited by 140
Self-citationFerraro, L., Tanganelli, S., O'Connor, W. T., Antonelli, T., Rambert, F. A., & Fuxé, K. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00182-3 · Cited by 137
Montplaisir, J. Y. (2000) · Sleep Medicine · doi:10.1016/s1389-9457(00)00014-9 · Cited by 137
Kales, A. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510150039009 · Cited by 133
Xyrem International Study Group (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.03.010 · Cited by 132
Comparative Polysomnographic Study of Narcolepsy and Idiopathic Central Nervous System Hypersomnia
Baker, T. L., Guilleminault, C., Nino‐Murcia, G., & Dement, W. C. (1986) · SLEEP · doi:10.1093/sleep/9.1.232 · Cited by 131
A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy
Moldofsky, H. (2000) · Sleep Medicine · doi:10.1016/s1389-9457(99)00014-3 · Cited by 129
Scheduled Naps in the Management of Daytime Sleepiness in Narcolepsy-Cataplexy
Mullington, J. M., & Broughton, R. (1993) · SLEEP · doi:10.1093/sleep/16.5.444 · Cited by 120
Treatment of Intractable Narcolepsy with a Monoamine Oxidase Inhibitor
Wyatt, R. J., Fram, D. H., Buchbinder, R., & Snyder, F. R. (1971) · New England Journal of Medicine · doi:10.1056/nejm197110282851802 · Cited by 120
Practice Parameters for the Treatment of Narcolepsy: An Update for 2000
Littner, M. R., Johnson, S. F., McCall, W. V., Anderson, W. M., Davila, D., Hartse, S. K., Kushida, C. A., Wise, M. S., Hirshkowitz, M., & Woodson, B. T. (2001) · SLEEP · doi:10.1093/sleep/24.4.451 · Cited by 115
Mitler, M. M., Hajduković, R., Erman, M. K., & Koziol, J. A. (1990) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199001000-00008 · Cited by 114
MAO-A and COMT polymorphisms and gene effects in narcolepsy
Dauvilliers, Y. A., Neidhart, E., Lecendreux, M., Billiard, M. M., & Tafti, M. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000911 · Cited by 113
Self-citationOn the Treatment of Rapid Eye Movement Narcolepsy
Guilleminault, C., Carskadon, M. A., & Dement, W. C. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490310092014 · Cited by 104
A Comparison of Three Different Sleep Schedules for Reducing Daytime Sleepiness in Narcolepsy
Rogers, A. E., Aldrich, M. S., & Lin, X. (2001) · SLEEP · doi:10.1093/sleep/24.4.385 · Cited by 102
Fluoxetine in the Treatment Of Cataplexy
Langdon, N., Shindler, J. S., Parkes, J. D., & Bandak, S. I. (1986) · SLEEP · doi:10.1093/sleep/9.2.371 · Cited by 90
Short-Term Triazolam Use Improves Nocturnal Sleep of Narcoleptics
Thorpy, M. J., Snyder, M., Alóe, F., Ledereich, P. S., & Starz, K. E. (1992) · SLEEP · doi:10.1093/sleep/15.3.212 · Cited by 89
Selegiline in the treatment of narcolepsy
Hublin, C., Partinen, M., Heinonen, E. H., Puukka, P. J., & Salmi, T. (1994) · Neurology · doi:10.1212/wnl.44.11.2095 · Cited by 88
Pharmacotherapy in narcolepsy.
Akimoto, H., HONDA, Y., & Takahashi, Y. (1960) · PubMed · Cited by 88
Stimulant and Anticataplectic Effects of Reboxetine in Patients with Narcolepsy: A Pilot Study
Larrosa, O., de la Llave, Y., Barrio, S., Granizo, J. J., & Garcı́a-Borreguero, D. (2001) · SLEEP · doi:10.1093/sleep/24.3.282 · Cited by 81
Treatment of narcolepsy with imipramine (Tofranil) and desmethylimipramine (Pertofran)
Hishikawa, Y., Ida, H., Nakai, K., & Kaneko, Z. (1966) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(66)90001-3 · Cited by 81
Dosing Regimen Effects of Modafinil for Improving Daytime Wakefulness in Patients With Narcolepsy
Schwartz, J. R. L., Feldman, N. T., Bogan, R., Nelson, M. T., & Hughes, R. J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200309000-00009 · Cited by 78
3. The Treatment of Excessive Somnolence With Stimulant Drugs
Mitler, M. M., Erman, M. K., & Hajduković, R. (1993) · SLEEP · doi:10.1093/sleep/16.3.203 · Cited by 76
Practice Parameters for the Use of Stimulants in the Treatment of Narcolepsy
Standards of Practice Committee of the American Sleep Disorders Association (1994) · SLEEP · doi:10.1093/sleep/17.4.348 · Cited by 76
The Effects of L-Dopa on Periodic Leg Movements and Sleep Organization in Narcolepsy
Boivin, D. B., Montplaisir, J. Y., & Poirier, G. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198908000-00012 · Cited by 73
Selegeline Hydrochloride Treatment in Narcolepsy. A Double-Blind, Placebo-Controlled Study
Mayer, G. J., Meier, K. E., & Hephata, K. (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199508000-00002 · Cited by 70
Self-citation1. Amphetamines and Narcolepsy: Use of the Stanford Database
Guilleminault, C. (1993) · SLEEP · doi:10.1093/sleep/16.3.199a · Cited by 68
Schmidt, H. S., Clark, R. W., & Pr, H. (1977) · American Journal of Psychiatry · doi:10.1176/ajp.134.2.183 · Cited by 65
Fluoxetine suppresses human cataplexy
Frey, J. L., & Darbonne, C. (1994) · Neurology · doi:10.1212/wnl.44.4.707 · Cited by 63
Amphetamine, mazindol, and fencamfamin in narcolepsy.
Shindler, J., Schachter, M., Brincat, S., & Parkes, J. D. (1985) · BMJ · doi:10.1136/bmj.290.6476.1167 · Cited by 59
Fluvoxamine and clomipramine in the treatment of cataplexy.
Schachter, M., & Parkes, J. D. (1980) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.43.2.171 · Cited by 58
Effects of bromocriptine on periodic limb movements in human narcolepsy
Boivin, D. B., Lorrain, D., & Montplaisir, J. Y. (1993) · Neurology · doi:10.1212/wnl.43.10.2134 · Cited by 52
Unusually prolonged rebound cataplexy after withdrawal of fluoxetine
Poryazova, R., Siccoli, M., Werth, E., & Bassetti, C. L. (2005) · Neurology · doi:10.1212/01.wnl.0000175978.61048.62 · Cited by 51
Self-citationSchuld, A., Kraus, T., Haack, M., Hinze‐Selch, D., & Pollmächer, T. (1999) · Journal of Sleep Research · doi:10.1046/j.1365-2869.1999.00162.x · Cited by 51
Self-citationBédard, M., Montplaisir, J. Y., Godbout, R., & Lapierre, O. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198902000-00004 · Cited by 47
Schrader, H., Kayed, K. S., Markset, A.-C. B., & Treidene, H. E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb03518.x · Cited by 46
Bédard, M., Montplaisir, J., Godbout, R., et al. (1989) · PubMed · Cited by 39
Yeh, S., & Schenck, C. H. (2004) · Sleep Medicine · doi:10.1016/j.sleep.2003.09.008 · Cited by 36
Untersuchung zur Komorbidität bei Narkolepsiepatienten
Mayer, G., Kesper, K., Peter, H., Ploch, T., Leinweber, T., & Peter, J. H. (2002) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2002-34207 · Cited by 33
Self-citationThe use of citalopram in resistant cataplexy
Thirumalai, S. S., & Shubin, R. A. (2000) · Sleep Medicine · doi:10.1016/s1389-9457(00)00026-5 · Cited by 23
Cited by
Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment
Bassetti, C. L. A., Adamantidis, A., Burdakov, D., Han, F., Gay, S., Kallweit, U., Khatami, R., Koning, F., Kornum, B. R., Lammers, G. J., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0226-9 · Cited by 646
Self-citationWilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Evidence‐Based Recommendations for the Assessment and Management of Sleep Disorders in Older Persons
Bloom, H. G., Ahmed, I., Alessi, C. A., Ancoli‐Israel, S., Buysse, D. J., Kryger, M. H., Phillips, B. A., Thorpy, M. J., Vitiello, M. V., & Zee, P. C. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02220.x · Cited by 464
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial
Dauvilliers, Y., Bassetti, C., Lammers, G. J., Arnulf, I., Mayer, G., Rodenbeck, A., Lehert, P., Ding, C.-L., Lecomte, J.-M., & Schwartz, J.-C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70225-4 · Cited by 362
Self-citationSzakacs, Z., Dauvilliers, Y., Mikhaylov, V., Poverennova, I., Krylov, S., Jankovic, S., Sonka, K., Lehert, P., Lecomte, I., Lecomte, J.-M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30333-7 · Cited by 338
Self-citation
Metadata
- Authors
- Billiard, M., Bassetti, C., Dauvilliers, Y., Dolenc‐Groselj, L., Lammers, G. J., Mayer, G., Pollmächer, T., Reading, P., & Sonka, K.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2006-09-20
- Volume
- 13
- Issue
- 10
- Pages
- 1035-1048
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W1978869736
- Cited by
- 255
- References
- 68
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.